Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Sickle Cell Disease-Pipeline Review, H1 2015

Sickle Cell Disease-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Sickle Cell Disease-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Sickle Cell Disease-Pipeline Review, H1 2015', provides an overview of the Sickle Cell Disease's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sickle Cell Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sickle Cell Disease and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Sickle Cell Disease

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Sickle Cell Disease and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Sickle Cell Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Sickle Cell Disease pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Sickle Cell Disease

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Sickle Cell Disease pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 7

Global Markets Direct Report Coverage 7

Sickle Cell Disease Overview 8

Therapeutics Development 9

Pipeline Products for Sickle Cell Disease-Overview 9

Pipeline Products for Sickle Cell Disease-Comparative Analysis 10

Sickle Cell Disease-Therapeutics under Development by Companies 11

Sickle Cell Disease-Therapeutics under Investigation by Universities/Institutes 14

Sickle Cell Disease-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Sickle Cell Disease-Products under Development by Companies 18

Sickle Cell Disease-Products under Investigation by Universities/Institutes 21

Sickle Cell Disease-Companies Involved in Therapeutics Development 22

Acceleron Pharma, Inc. 22

Acetylon Pharmaceuticals, Inc. 23

Addex Therapeutics Ltd 24

Advinus Therapeutics Ltd. 25

Alnylam Pharmaceuticals, Inc. 26

Bluebird bio, Inc. 27

Bristol-Myers Squibb Company 28

Daiichi Sankyo Company, Limited 29

Dilaforette AB 30

Emmaus Medical, Inc. 31

Errant Gene Therapeutics, LLC 32

Erytech Pharma SA 33

Gamida Cell Ltd. 34

Gilead Sciences, Inc. 35

Global Blood Therapeutics, Inc. 36

Isis Pharmaceuticals, Inc. 37

Johnson & Johnson 38

Morphogenesis, Inc. 39

NKT Therapeutics, Inc. 40

Novartis AG 41

Pfizer Inc. 42

PharmaEssentia Corporation 43

Prolong Pharmaceuticals 44

ReveraGen BioPharma, Inc. 45

Sangamo BioSciences, Inc. 46

Sanofi 47

SynZyme Technologies, LLC 48

Sickle Cell Disease-Therapeutics Assessment 49

Assessment by Monotherapy Products 49

Assessment by Target 50

Assessment by Mechanism of Action 52

Assessment by Route of Administration 54

Assessment by Molecule Type 56

Drug Profiles 58

ACY-957-Drug Profile 58

ADX-85142-Drug Profile 59

ADX-94819-Drug Profile 60

AIC-2011-Drug Profile 61

AIC-6020-Drug Profile 62

ALN-TMP-Drug Profile 63

Antisense Oligonucleotides to Inhibit BCL11A and KLF1 for Hematological Disorders-Drug Profile 64

apixaban-Drug Profile 65

BAX-555-Drug Profile 67

BB-305-Drug Profile 69

CNTO-530-Drug Profile 71

Didox-Drug Profile 72

Drugs to Inhibit PRMT5 for Sickle Cell Anemia-Drug Profile 76

EdX-17-Drug Profile 77

Enhoxy-Drug Profile 78

GBT-440-Drug Profile 79

Gene Therapy for Sickle Cell Anemia-Drug Profile 80

Gene Therapy for Sickle Cell Disease-Drug Profile 81

Gene Therapy for Sickle Cell Disease and Beta Thalassemia-Drug Profile 82

Gene Therapy for Sickle Cell Disease and Thalassemia-Drug Profile 83

Gene Therapy to Activate Gamma Globin for Sickle Cell Disease-Drug Profile 84

glutamine-Drug Profile 85

luspatercept-Drug Profile 87

NiCord-Drug Profile 88

NKTT-120-Drug Profile 89

panobinostat-Drug Profile 90

PB-04-Drug Profile 96

PF-4447943-Drug Profile 97

plerixafor-Drug Profile 98

PNQ-103-Drug Profile 100

prasugrel hydrochloride-Drug Profile 101

Protein for Sickle Cell Disease-Drug Profile 104

regadenoson-Drug Profile 105

RN-1-Drug Profile 107

Sanguinate-Drug Profile 108

SCD-101-Drug Profile 110

SCPF-Drug Profile 111

sevuparin sodium-Drug Profile 112

Small Molecule for Beta Thalassemia and Sickle Cell Anemia-Drug Profile 114

Small Molecule to Agonize A2A for Immunology, Hematological and Neurological Disorders-Drug Profile 115

Small Molecule to Inhibit KDM1A for AML, MDS and Sickle Cell Disease-Drug Profile 116

Small Molecules to Antagonize TNFR1 for Immunology, Gastrointestinal, Neurology and Hematological Disorders-Drug Profile 117

Small Molecules to Inhibit HDAC for Oncology and Sickle Cell Disease-Drug Profile 118

Small Molecules to Inhibit PRMT5 for Haemoglobinopathies and Solid Tumours-Drug Profile 119

Stem Cell Therapy to Activate Beta Globin for Sickle Cell Disease-Drug Profile 120

Trichosic-Drug Profile 121

VBP-15-Drug Profile 122

VitalHeme-Drug Profile 124

Sickle Cell Disease-Recent Pipeline Updates 126

Sickle Cell Disease-Dormant Projects 155

Sickle Cell Disease-Discontinued Products 157

Sickle Cell Disease-Product Development Milestones 158

Featured News & Press Releases 158

Appendix 164

Methodology 164

Coverage 164

Secondary Research 164

Primary Research 164

Expert Panel Validation 164

Contact Us 164

Disclaimer 165

List of Tables

Number of Products under Development for Sickle Cell Disease, H1 2015 12

Number of Products under Development for Sickle Cell Disease-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 15

Number of Products under Development by Companies, H1 2015 (Contd..1) 16

Number of Products under Investigation by Universities/Institutes, H1 2015 17

Comparative Analysis by Late Stage Development, H1 2015 18

Comparative Analysis by Clinical Stage Development, H1 2015 19

Comparative Analysis by Early Stage Development, H1 2015 20

Products under Development by Companies, H1 2015 21

Products under Development by Companies, H1 2015 (Contd..1) 22

Products under Development by Companies, H1 2015 (Contd..2) 23

Products under Investigation by Universities/Institutes, H1 2015 24

Sickle Cell Disease-Pipeline by Acceleron Pharma, Inc., H1 2015 25

Sickle Cell Disease-Pipeline by Acetylon Pharmaceuticals, Inc., H1 2015 26

Sickle Cell Disease-Pipeline by Addex Therapeutics Ltd, H1 2015 27

Sickle Cell Disease-Pipeline by Advinus Therapeutics Ltd., H1 2015 28

Sickle Cell Disease-Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015 29

Sickle Cell Disease-Pipeline by Bluebird bio, Inc., H1 2015 30

Sickle Cell Disease-Pipeline by Bristol-Myers Squibb Company, H1 2015 31

Sickle Cell Disease-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 32

Sickle Cell Disease-Pipeline by Dilaforette AB, H1 2015 33

Sickle Cell Disease-Pipeline by Emmaus Medical, Inc., H1 2015 34

Sickle Cell Disease-Pipeline by Errant Gene Therapeutics, LLC, H1 2015 35

Sickle Cell Disease-Pipeline by Erytech Pharma SA, H1 2015 36

Sickle Cell Disease-Pipeline by Gamida Cell Ltd., H1 2015 37

Sickle Cell Disease-Pipeline by Gilead Sciences, Inc., H1 2015 38

Sickle Cell Disease-Pipeline by Global Blood Therapeutics, Inc., H1 2015 39

Sickle Cell Disease-Pipeline by Isis Pharmaceuticals, Inc., H1 2015 40

Sickle Cell Disease-Pipeline by Johnson & Johnson, H1 2015 41

Sickle Cell Disease-Pipeline by Morphogenesis, Inc., H1 2015 42

Sickle Cell Disease-Pipeline by NKT Therapeutics, Inc., H1 2015 43

Sickle Cell Disease-Pipeline by Novartis AG, H1 2015 44

Sickle Cell Disease-Pipeline by Pfizer Inc., H1 2015 45

Sickle Cell Disease-Pipeline by PharmaEssentia Corporation, H1 2015 46

Sickle Cell Disease-Pipeline by Prolong Pharmaceuticals, H1 2015 47

Sickle Cell Disease-Pipeline by ReveraGen BioPharma, Inc., H1 2015 48

Sickle Cell Disease-Pipeline by Sangamo BioSciences, Inc., H1 2015 49

Sickle Cell Disease-Pipeline by Sanofi, H1 2015 50

Sickle Cell Disease-Pipeline by SynZyme Technologies, LLC, H1 2015 51

Assessment by Monotherapy Products, H1 2015 52

Number of Products by Stage and Target, H1 2015 54

Number of Products by Stage and Mechanism of Action, H1 2015 56

Number of Products by Stage and Route of Administration, H1 2015 58

Number of Products by Stage and Molecule Type, H1 2015 60

Sickle Cell Disease Therapeutics-Recent Pipeline Updates, H1 2015 129

Sickle Cell Disease-Dormant Projects, H1 2015 158

Sickle Cell Disease-Dormant Projects (Contd..1), H1 2015 159

Sickle Cell Disease-Discontinued Products, H1 2015 160

List of Figures

Number of Products under Development for Sickle Cell Disease, H1 2015 12

Number of Products under Development for Sickle Cell Disease-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 14

Number of Products under Investigation by Universities/Institutes, H1 2015 17

Comparative Analysis by Clinical Stage Development, H1 2015 19

Comparative Analysis by Early Stage Products, H1 2015 20

Assessment by Monotherapy Products, H1 2015 52

Number of Products by Top 10 Targets, H1 2015 53

Number of Products by Stage and Top 10 Targets, H1 2015 53

Number of Products by Top 10 Mechanism of Actions, H1 2015 55

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 55

Number of Products by Top 10 Routes of Administration, H1 2015 57

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 58

Number of Products by Top 10 Molecule Types, H1 2015 59

Number of Products by Stage and Top 10 Molecule Types, H1 2015 60

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Acceleron Pharma, Inc.

Acetylon Pharmaceuticals, Inc.

Addex Therapeutics Ltd

Advinus Therapeutics Ltd.

Alnylam Pharmaceuticals, Inc.

Bluebird bio, Inc.

Bristol-Myers Squibb Company

Daiichi Sankyo Company, Limited

Dilaforette AB

Emmaus Medical, Inc.

Errant Gene Therapeutics, LLC

Erytech Pharma SA

Gamida Cell Ltd.

Gilead Sciences, Inc.

Global Blood Therapeutics, Inc.

Isis Pharmaceuticals, Inc.

Johnson & Johnson

Morphogenesis, Inc.

NKT Therapeutics, Inc.

Novartis AG

Pfizer Inc.

PharmaEssentia Corporation

Prolong Pharmaceuticals

ReveraGen BioPharma, Inc.

Sangamo BioSciences, Inc.

Sanofi

SynZyme Technologies, LLC

Sickle Cell Disease Therapeutic Products under Development, Key Players in Sickle Cell Disease Therapeutics, Sickle Cell Disease Pipeline Overview, Sickle Cell Disease Pipeline, Sickle Cell Disease Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com